Journal article

Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

Katharine K Brieger, Siri Peterson, Alice W Lee, Bhramar Mukherjee, Kelly M Bakulski, Aliya Alimujiang, Hoda Anton-Culver, Michael S Anglesio, Elisa Bandera, Andrew Berchuck, David DL Bowtell, Georgia Chenevix-Trench, Kathleen R Cho, Daniel W Cramer, Anna DeFazio, Jennifer A Doherty, Renee T Fortner, Dale W Garsed, Simon A Gayther, Aleksandra Gentry-Maharaj Show all

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2020

Abstract

PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival. METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone ..

View full abstract

Grants

Awarded by Ovarian Cancer Research Fund


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by National Health & Medical Research Council of Australia


Awarded by Cancer Foundation of Western Australia


Awarded by National Institutes of Health


Awarded by German FederalMinistry of Education and Research, Programme of Clinical Biomedical Research


Awarded by U.S. National Institutes of Health


Awarded by Department of Defense


Awarded by NCI


Awarded by National Cancer Institute, Bethesda, MD


Awarded by Danish Cancer Society, Copenhagen, Denmark


Awarded by National Cancer Institute


Awarded by National Health andMedical Research Council (NHMRC) of Australia


Awarded by Lon V Smith Foundation


Awarded by MRC


Awarded by California Cancer Research Program



Funding Acknowledgements

The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Funding for individual studies: AUS: The AustralianOvarian Cancer Study (AOCS) was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (MultiState Applications 191, 211 and 182). AOCS gratefully acknowledges additional support fromOvarian Cancer Australia and the PeterMacCallum Foundation; CON: National Institutes of Health (R01-CA063678, R01CA074850; R01-CA080742); DOV: National Institutes of Health R01CA112523 and R01-CA87538; GER: German FederalMinistry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ); HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC67001); HOP: University of Pittsburgh School ofMedicine Dean's Faculty Advancement Award (F. Modugno), Department of Defense (DAMD1702-1-0669) and NCI (K07-CA080668, R01-CA95023, P50-CA159981, MO1-RR000056, R01-CA126841); MAL: Funding for this studywas provided by research grant R01-CA61107 from the National Cancer Institute, Bethesda, MD, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project; MAY: National Institutes of Health (R01-CA122443, P30-CA15083, P50CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey; OPL: National Health andMedical Research Council (NHMRC) of Australia (APP1025142, APP1120431) and BrisbaneWomen's Club; POL: Intramural Research Program of the National Cancer Institute; UCI: NIH R01-CA058860 and the Lon V Smith Foundation grant LVS-39420; UKO: The UKOPS studywas funded by The Eve Appeal (The Oak Foundation) with investigators supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and MRC Core Funding (MR_UU_12023); USC: P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200).